JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $300 to $310.
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $300 to $310.